Bringing the very best science and medicine to our best equine friends

NEWS

Kindred Biosciences Announces Fourth Quarter and Year-End 2014 Financial Results

San Francisco, CA (March 12, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended December 31, 2014. Conference Call and Webcast at 4:30 p.m. Eastern / 1:30 p.m. Pacific KindredBio today announced its fourth quarter financial results and provided updates on its programs. Development Updates KindredBio continues to build and advance its pipeline, including biologics, and now has over 20 programs across multiple product candidates and indications. Some of the key programs are highlighted below. The pivotal field trial of SentiKind, a KCNQ potassium channel agonist, for post-operative pain in dogs is currently enrolling patients …

Continue Reading

KindredBio to Announce Fourth Quarter and Year-End 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 12, 2015 SAN FRANCISCO, California. (March 3, 2015) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its fourth quarter and year-end 2014 financial results on March 12, 2015 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.

Continue Reading

KindredBio to Announce Third Quarter 2014 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2014 SAN FRANCISCO, California. (November 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its third quarter 2014 financial results on November 13, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day. Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 32324288. The call …

Continue Reading

Kindred Biosciences Announces Second Quarter 2014 Financial Results

San Francisco, CA (August 13, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended June 30, 2014. Conference Call and Webcast at 4:30 p.m. Eastern / 1.30 p.m. Pacific “It is an exciting time for KindredBio as we develop our broad portfolio of drug candidates,” stated Richard Chin, M.D., President and Chief Executive Officer of KindredBio. “We currently anticipate the topline results from our pivotal study of CereKin shortly. The fact that we completed the entire study from start to finish in only 12 months, and on budget, is a testament to the quality and …

Continue Reading

Kindred Biosciences Announces First Quarter 2014 Financial Results and Completion of Enrollment in CereKin Pivotal Study

San Francisco, CA (May 12, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended March 31, 2014. In addition, KindredBio announced that it has completed enrollment in KB010, its pivotal study for CereKinTM (diacerein).

Continue Reading

KindredBio to Announce First Quarter 2014 Financial Results on Monday, May 12th

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time that Day SAN FRANCISCO, California. (May 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its first quarter 2014 financial results on May 12, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.

Continue Reading

KindredBio Announces Closing of Public Offering and Exercise of Over-Allotment Option

SAN FRANCISCO, California. (April 8, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of its public offering of 3,450,000 shares of its common stock, including 450,000 shares sold pursuant to the exercise in full by the underwriters of their over-allotment option, at a public offering price of $18.00 per share. KindredBio estimates net proceeds from the offering to be approximately $58.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Continue Reading